Bharat parenterals Limited has officially responded to BSE Limited's inquiry regarding significant movement in the company's stock price, clarifying that no undisclosed material information is affecting the securities' performance. The WHO-GMP certified pharmaceutical company addressed BSE's concerns through an official communication dated April 10, 2026.

BSE Inquiry and Company Response

The BSE had sought clarification through reference number L/SURV/ONL/PV/APJ/2026-2027/3578 dated April 9, 2026, regarding notable price movements in Bharat Parenterals' securities. The company's response addressed key concerns about potential undisclosed information affecting stock performance.

Regulatory Compliance Confirmation

Bharat Parenterals Limited confirmed its full compliance with regulatory requirements and disclosure obligations. The company emphasized its adherence to established market regulations and transparency standards.

Key compliance aspects highlighted include:

• Full compliance with Regulation 30 of SEBI Listing Regulations
• Prompt disclosure of all material information to stock exchanges
• Adherence to Securities and Exchange Board of India requirements
• Maintenance of transparency in corporate communications

Market-Driven Price Movement

The pharmaceutical company attributed the recent stock price movements to market forces rather than any specific corporate developments. Company Secretary and Compliance Officer Sharmin Soni signed the official response, reaffirming the organization's commitment to maintaining high corporate governance standards.

Corporate Information

Bharat Parenterals Limited operates as a WHO-GMP certified pharmaceutical company with Star Export House status. The company maintains its registered office and manufacturing facilities at Survey No. 144-A, Jarod-Samlaya Road, Village Haripura, Taluka Savli, District Vadodara, Gujarat.

The company's response reinforces its commitment to regulatory compliance and transparent communication with stakeholders while addressing market concerns about stock price volatility.

Bharat Parenterals Limited has issued a formal notice to its physical shareholders regarding a special window for re-lodgement of share transfer deeds, following regulatory compliance requirements under SEBI guidelines.

Regulatory Compliance Notice

The company published newspaper advertisements on April 08, 2026, in two prominent publications to ensure wide reach among shareholders. The notice appeared in the Ahmedabad Edition of "Business Standard" and the Vadodara Edition of "Vadodara Samachar", with the advertisement also made available on the company's website at www.bplindia.in .

SEBI Circular Implementation

The notice follows SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026, which established specific guidelines for physical share transfers. The regulatory framework addresses transfer deeds that were previously rejected due to document deficiencies or procedural issues.

Shareholder Guidelines

Eligible physical shareholders can re-lodge their share transfer deeds for processing within the specified timeframe. The company emphasized that only transfer deeds originally lodged before the April 01, 2019 deadline and subsequently rejected due to deficiencies will be considered for re-lodgement.

Transfer requests must be submitted along with requisite documents to the company's Registrar and Share Transfer Agent (R&TA) at Adroit Corporate Services Pvt. Ltd., located at 18-20, Jafferbhoy Industrial Estate, 1st Floor, Makwana Road, Marol Naka, Andheri East, Mumbai, Maharashtra-400059, or via email at info@adroitcorporate.com .

Processing Requirements

The company clarified that re-lodged shares for transfer will be processed exclusively in dematerialized form, following the due process prescribed by SEBI. Transfer deeds lodged after the April 01, 2019 deadline and rejected by the company will not be entertained under this special window provision.

The notice was signed by Sharmin Soni, Company Secretary and Compliance Officer (ICSI M. No: ACS-75694), ensuring proper authorization and regulatory compliance for the communication to shareholders.